Quadruple-Action Anticancer Prodrug

  • Author: Angewandte Chemie International Edition
  • Published: 14 September 2017
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Angewandte Chemie International Edition/Wiley-VCH
  • Associated Societies: Gesellschaft Deutscher Chemiker (GDCh), Germany
thumbnail image: Quadruple-Action Anticancer Prodrug

Cisplatin, an anticancer drug, is widely used for chemotherapy. However, its usefulness is limited by the resistance that tumors develop to the drug. Overcoming this resistance is a major clinical challenge.


Dan Gibson, The Hebrew University of Jerusalem, Israel, and colleagues have prepared a dinuclear Pt(IV) "quadruple action" prodrug (pictured) designed to overcome resistance. Inside cancer cells, this prodrug releases four different bioactive moieties, each acting on different cellular targets, that combine synergistically to kill the cells. The prodrug was obtained by linking the Pt(IV) derivatives of cisplatin with dichloroacetate and [Pt(1S,2S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)]2+ with phenylbutyrate.

The prodrug is extremely potent against a panel of cancer cells. It is 200–450 times more effective than cisplatin against pancreatic and colon KRAS mutated cells, a mutation that is the cause of most pancreatic and colon cancers. For more than three decades, attempts to find an inhibitor failed and, to date, KRAS had been considered "undruggable". These quadruple-action prodrugs thus represent a major step in anticancer therapy.


 

Article Views: 509

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH